Skip to main content

Eflornithine Dosage

Medically reviewed by Drugs.com. Last updated on Feb 13, 2024.

Applies to the following strengths: 192 mg

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Neuroblastoma

Body Surface Area (BSA)
BSA greater than 1.5 m2: 768 mg (four tablets) orally twice a day
BSA 0.75 to 1.5 m2: 576 mg (three tablets) orally twice a day
BSA 0.5 to less than 0.75 m2: 384 mg (two tablets) orally twice a day
BSA 0.25 to less than 0.5 m2: 192 mg (one tablet) orally twice a day

Duration: For 2 years or until recurrence of disease or unacceptable toxicity.

Comments:


Use: To reduce the risk of relapse in patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy, including anti-GD2 immunotherapy

Usual Pediatric Dose for Neuroblastoma

Body Surface Area (BSA)
BSA greater than 1.5 m2: 768 mg (four tablets) orally twice a day
BSA 0.75 to 1.5 m2: 576 mg (three tablets) orally twice a day
BSA 0.5 to less than 0.75 m2: 384 mg (two tablets) orally twice a day
BSA 0.25 to less than 0.5 m2: 192 mg (one tablet) orally twice a day

Duration: For 2 years or until recurrence of disease or unacceptable toxicity.

Comments:


Use: To reduce the risk of relapse in patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy, including anti-GD2 immunotherapy

Renal Dose Adjustments

Liver Dose Adjustments

Liver dysfunction: Data not available; pharmacokinetic (PK) analyses report no clinical meaningful effects in patients with mild liver dysfunction. No PK data is available for patients with moderate or severe liver dysfunction.

Hepatotoxicity (AST or ALT 10 times ULN or greater):

Dose Adjustments

Recommended dose reductions for toxicity management:
Current dose: 768 mg (four tablets) orally twice a day
Recommended reduced dose: 576 mg (three tablets) orally twice a day

Current dose: 576 mg (three tablets) orally twice a day
Recommended reduced dose: 384 mg (two tablets) orally twice a day

Current dose: 384 mg (two tablets) orally twice a day
Recommended reduced dose: 192 mg (one tablet) orally twice a day

Current dose: 192 mg (one tablet) orally twice a day
Recommended reduced dose: 192 mg (one tablet) orally once daily


Recommended dosage modifications for the management of adverse reactions:
Myelosuppression:
Neutrophil count less than 500/mm3:

Platelet count less than 25,000/mm3:

Anemia (less than 8 g/dL):

Hearing loss (clinically concerning new or worsening hearing loss compared to baseline audiogram):

Grade 3:

Grades 3 or 4:

Recurrent grade 4:

Precautions

CONTRAINDICATIONS: None

Safety and efficacy have not been established in patients younger than 1 year.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:


Storage requirements:

Monitoring:
Hematologic: Blood cell counts before and during treatment
Hepatic: Liver function tests before and during treatment
Other: Hearing loss: Audiogram before and during treatment

Patient advice:

Does Eflornithine interact with my other drugs?

Enter medications to view a detailed interaction report using our Drug Interaction Checker.

More about eflornithine

Patient resources

Other brands

Iwilfin

Professional resources

Other brands

Iwilfin

Related treatment guides

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.